NEW YORK, NY / ACCESSWIRE / March 6, 2018 / U.S. markets rallied Monday, with the Dow breaking a streak of 4 consecutive losses, as concerns over a potential trade war eased. The Dow Jones Industrial Average spiked 1.37 percent to close at 24,874.76, while the S&P 500 Index jumped 1.1 percent to close at 2,720.94. The Nasdaq Composite Index increased to close at 7,330.70. The Dow and S&P 500 recorded losses of 3 percent and 2 percent, respectively, last week.
"I see today's rebound as more of a technical bounce. After two days of declines on big volume last week, stocks are bouncing back today on light volume. This suggests that the bears have backed off for now, allowing the market to recover a bit. We may also be seeing a bit of bargain hunting or short covering," said Colin Cieszynski, chief market strategist at SIA Wealth Management, according to MarketWatch.
RDI Initiates Coverage on:
GlycoMimetics' stock moved 5.90% lower Monday, to close the day at $22.82. The stock recorded a trading volume of 2,076,310 shares, which was above its three months average volume of 707.191 shares. In the last year, GlycoMimetics' shares have traded in a range of 3.82 - 26.05. The share price has gained 497.38% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $23.05 is greater than its 200-day moving average of $15.75. Shares of GlycoMimetics have gained roughly 5.21 percent in the past month and are up 35.91 percent year-to-date.
Access RDI's GlycoMimetics, Inc. Research Report at:
On Monday, shares of Vericel recorded a trading volume of 9,609,942 shares, which was above the three months average volume of 693,183 shares. The stock ended the day 41.92% higher at 11.85. The share price has gained 404.26% from its 52 week low with a 52 week trading range of 2.35 - 12.05.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $7.26 is greater than its 200-day moving average of $5.30. Shares of Vericel have gained roughly 66.9 percent in the past month and are up 117.43 percent year-to-date.
Access RDI's Vericel Corporation Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.